RxDoctor Payments Data

Daryl Lapeyrolerie, MD

Internal Medicine · Greenville, SCNPI 1699728600

Payments from drug & device makers

$342in general payments, 2019–2025

Across 21 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$195
  • AbbVie$63
  • Lilly USA, LLC$48
  • GSK$22
  • Amgen$14

What the payments were for

  • Food & beverage$342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk13$195
AbbVie3$63
Lilly USA, LLC3$48
GSK1$22
Amgen1$14

How this compares

$342 in reported general payments places this provider in the 50th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$118,418
Medicare patients
155
Services billed
1,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin84$93,887
OzempicSemaglutide44$58,461
TrulicityDulaglutide28$48,389
Repatha SureclickEvolocumab32$37,660
FarxigaDapagliflozin Propanediol22$23,618
JanuviaSitagliptin Phosphate16$15,465
MounjaroTirzepatide11$14,256
TradjentaLinagliptin12$11,091
LinzessLinaclotide12$9,803
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,286
XareltoRivaroxaban13$8,377
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$6,830
InvokanaCanagliflozin12$6,755
Breo ElliptaFluticasone/Vilanterol12$4,760
Diltiazem 24hr Er (Cd)Diltiazem Hcl58$2,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$48$62,64639 claims
Novo NordiskOzempic$195$58,46144 claims
AbbVieLinzess, Synthroid$63$10,37726 claims
GSKBreo Ellipta$22$4,76012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →